13 Oct 2026, 10:04 IST
Aster DM Quality Care Limited
HDFC Securities · ADD
The report estimates a Sales/EBITDA impact of 0.6%/2.7% from the oncology drug price cap and maintains an ADD rating.
From Healthcare Services Sector Update Oct26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.